Dr. Michael T. Schweizer
Daily News: What inspired you to attend the 2017 GU Cancers Symposium?
Dr. Schweizer: I first attended the Symposium back in 2013 after my research mentor suggested that we submit an abstract to the meeting. Overall, I’ve found it to be a great forum to hear about the latest in GU cancers research. Because most of the GU oncology thought leaders are in attendance, there are ample opportunities for networking.
Daily News: How has research presented at the GU Cancers Symposium affected how you practice?
Dr. Schweizer: The IMvigor 210 study was presented last year, which ultimately led to the approval of atezolizumab as a second-line therapy for advanced bladder cancer. I now routinely prescribe atezolizumab to my patients with bladder cancer that has progressed on frontline platinum chemotherapy as a result of this trial.
Daily News: Why is it important for early-career oncologists to attend the GU Cancers Symposium?
Dr. Schweizer: For anyone focused on GU oncology, the Symposium is a great forum to present your research, meet potential collaborators, or just catch up on the latest in GU cancers research. I always feel more informed and better connected with the GU oncology community after attending.
Daily News: What sessions are you most looking forward to attending this year and why?
Dr. Schweizer: I always make sure I catch the prostate and bladder cancer Oral Abstract Sessions, which are the two tumor types I see the most often. I also walk through the Poster Sessions, which provide an opportunity to talk with investigators directly. I am also looking forward to the prostate cancer year in review and keynote lecture.
Daily News: How will you plan your time during the GU Cancers Symposium?
Dr. Schweizer: I find the iPlanner app really helpful in planning my time at the meeting. There is so much to see, and the app provides a way to keep everything organized.
Daily News: What advice do you have for first-time attendees to get the most out of their meeting experience?
Dr. Schweizer: I recommend reviewing the abstracts online prior to attending. It’s impossible to see everything, and by doing a little homework in anticipation of the meeting, you can be sure you learn about the topics that interest you the most.
About Dr. Schweizer: Dr. Schweizer is a medical oncologist. He is an assistant professor at the University of Washington School of Medicine and an assistant member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center. His research interest is translational genitourinary cancer.